Metabolite produced by gut microbiota from pomegranates reduces inflammatory bowel disease

Medical Xpress | January 09, 2019

Scientists at the University of Louisville have shown that a microbial metabolite, Urolithin A, derived from a compound found in berries and pomegranates, can reduce and protect against inflammatory bowel disease (IBD). Millions of people worldwide suffer from IBD in the form of either ulcerative colitis or Crohn's disease, and few effective long-term treatments are available. The researchers at UofL have determined that Urolithin A (UroA) and its synthetic counterpart, UAS03, mitigate IBD by increasing proteins that tighten epithelial cell junctions in the gut and reducing gut inflammation in animal models. Tight junctions in the gut barrier prevent inappropriate microorganisms and toxins from leaking out, causing inflammation characteristic of IBD. Preclinical research published today in Nature Communications shows the mechanism by which UroA and UAS03 not only reduce inflammation and restore gut barrier integrity but also protect against colitis. "The general belief thus far in the field is that urolithins exert beneficial effects through their anti-inflammatory, anti-oxidative properties. We have for the first time discovered that their mode of function also includes repairing the gut barrier dysfunction and maintaining barrier integrity," said Rajbir Singh, Ph.D., a postdoctoral fellow at UofL and the paper's first author.

Spotlight

This White Paper is a joint collaboration between the European Cancer Patients Coalition (ECPC) and Eurocarers, aimed at presenting European policy-makers at the European Union (EU) and national level with policy recommendations for a robust policy framework supporting cancer carers. Carers are people who provide unpaid care to someone with a chronic illness, disability or other long-lasting health or care need, outside of a professional or formal framework.

Spotlight

This White Paper is a joint collaboration between the European Cancer Patients Coalition (ECPC) and Eurocarers, aimed at presenting European policy-makers at the European Union (EU) and national level with policy recommendations for a robust policy framework supporting cancer carers. Carers are people who provide unpaid care to someone with a chronic illness, disability or other long-lasting health or care need, outside of a professional or formal framework.

Related News

MEDICAL

Novalis Biotech Announces the Closing of a €25 Million Biotech Acceleration Fund

Novalis Biotech | July 01, 2021

Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs). The Biotech Acceleration Fund will continue to invest in start-up and scale-up companies that use "enabling technologies" to improve healthcare. Genomic and bioinformatics technologies, drug research and manufacturing tools, diagnostics, and personalized medicine are examples. The funds will be divided between early-stage incubation initiatives and late-stage acceleration programs. Grapheal and RheaVita have already made investments in the enabling technologies they are developing. Novalis will continue to use its strong network in the Benelux area and intends to expand its investments throughout Western Europe and the United States. Novalis invests early and focuses on capital-light ideas where modest investments can generate substantial value using software, intellectual property, tools, and other enabling technologies that can transform healthcare. Novalis has a strong track record of turning ideas into profitable businesses by using extensive networks. Novalis Fund 1 was established in September 2018 with a total capitalization of €4 million, which was invested in eight companies, the majority of which were located in the Benelux region. BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO, and OHMX.bio are among them. A first exit occurred when doc.ai, a US portfolio company, was acquired by Sharecare as part of an IPO. About Novalis Biotech Acceleration Novalis Biotech is an early-stage venture capital investor in healthcare-revolutionizing technologies. The company's main competence is digitalization in the life sciences, focusing on capital-light "enabling technologies" such as bioinformatics, artificial intelligence, genomics, personalized medicine, research or manufacturing tools, and diagnostics.

Read More

CDI Labs Announces the Addition of Its SARS-CoV-2 (COVID19) Assay Platform

PR Newswire | August 21, 2020

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all known viruses as well as epitope level data on COVID19 antibodies. In addition, CDI has added the COVID19 S and N proteins to CDI's HuProtTM proteome microarray. CDI's VirScan is the first commercial use of the incredibly powerful PhIP-seq technology (Xu, George J et al. SARS-COV-2 "Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome." Science (New York, N.Y.) vol. 348,6239 (2015): aaa0698. doi:10.1126/science.aaa0698). These p

Read More

CELL AND GENE THERAPY

Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology

Matica Biotechnology, Inc. | October 19, 2021

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production. Michael Stewart, Chief Technology Officer at Matica Bio explained, "The generation of in-line real-time process data is one of the most significant obstacles to achieving consistent, high-producing viral vector titers during development that can be translatable to large scale production. In many respects, what is going on inside a bioreactor or within downstream operations is still a black box to us." Mr. Stewart continued, "Matica Bio's development, manufacturing and quality teams have decades of viral vector production experience. Applying our expertise together with Sartorius' industry-leading single-use and PAT technologies will allow us to provide more robust, consistent results for our clients, guiding informed decision-making throughout the manufacturing process and accelerating the overall development timeline to the clinic and market." "We are extremely excited to initiate this partnership with Sartorius. Our number one priority is to deliver for our clients. Our expert staff will be working to integrate more fully automated processes leading to an increase in the speed of information flow and a reduction in preventable errors. The end result will be increased product yields, higher quality as well as improved flexibility and responsiveness to our clients' ever-changing needs." Dr. Yun Jeong Song, Chief Executive Officer of Matica Bio The JRA with Sartorius underscores Matica Bio's commitment to applying integrated technology and bioprocess solutions to address production complexities like reduction of labor and risk while improving output efficiencies in the production of advanced therapies, including viral vector products. Together Sartorius and Matica Bio are dedicated to solving the challenges of large-scale cell culture and viral vector production, improving manufacturability and reducing the costs of novel cell and gene therapies, oncolytic vectors and vaccines. About Matica Biotechnology, Inc. Matica Bio is a contract development and manufacturing organization for gene therapies, cell therapies, vaccines, oncolytic vectors and other advanced biotherapeutic products. Our GMP facility in College Station, TX is designed for the rapid development, scale-up and production of clinical and commercial supply. Matica Bio offers process development, GMP production, product release and stability assessment, together with the quality oversight and regulatory guidance necessary to ensure our clients' success.

Read More